Cart
sales@molnova.com
Hexahydrocurcumin
CAS No. 36062-05-2
Hexahydrocurcumin( —— )
Catalog No. M24319 CAS No. 36062-05-2
Hexahydrocurcumin is a selective, orally active COX-2 inhibitor and inactive against COX-1.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 311 | In Stock |
|
| 5MG | 188 | In Stock |
|
| 10MG | 312 | In Stock |
|
| 25MG | 629 | In Stock |
|
| 50MG | 918 | In Stock |
|
| 100MG | 1293 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameHexahydrocurcumin
-
NoteResearch use only, not for human use.
-
Brief DescriptionHexahydrocurcumin is a selective, orally active COX-2 inhibitor and inactive against COX-1.
-
DescriptionHexahydrocurcumin is a selective, orally active COX-2 inhibitor and inactive against COX-1.
-
In VitroHexahydrocurcumin (0-25 μM; 24-48 hours; HT-29 cells) treatment significantly decreased the viability of HT-29 colon cancer cells in a time- and concentration-dependent. The respective IC50 values for 24 and 48 h of Hexahydrocurcumin exposureare 77.05 and 56.95, respectively.Hexahydrocurcumin (0-25 μM; 24-48 hours; HT-29 cells) combined with 5-fluorouracil (5-FU; 5 μM) markedly reduces the COX-2 expression. The level of COX-1 is not altered.Hexahydrocurcumin (0-25 μM; 24-48 hours; HT-29 cells) combined with 5-fluorouracil (5-FU; 5 μM) markedly reduces the COX-2 protein. The level of COX-1 protein is not altered.Hexahydrocurcumin (7-14 μM; 24 hours) attenuates lipopolysaccharide (LPS)-elicited increase of prostaglandin E2 (PGE2) in murine macrophages (RAW 264.7) in a concentration-dependent manner. Cell Viability Assay Cell Line:HT-29 cells Concentration:0 μM, 5 μM, 10 μM, 25 μM Incubation Time:24 hours or 48 hours Result:Significantly decreased the viability of HT-29 colon cancer cells.RT-PCR Cell Line:HT-29 cells Concentration:25 μM Incubation Time:24 hours Result:Combined with 5-fluorouracil (5-FU; 5 μM) markedly reduced the COX-2 expression.Western Blot Analysis Cell Line:HT-29 cells Concentration:25 μM Incubation Time:24 hours Result:Combined with 5-fluorouracil (5-FU; 5 μM) markedly reduced the COX-2 protein.
-
In VivoHexahydrocurcumin (50 mg/kg; oral administration; daily; for 16 weeks; male Wistar rats) treatment significantly reduces the numbers of aberrant crypt foci (ACF) in colon cancer rats. Hexahydrocurcumin also markedly decreases COX-2 protein expression. The levels of COX-1 protein is not different from normal rats. Animal Model:Male Wistar rats (100-120 g) injected with dimethylhydrazine (DMH) Dosage:50 mg/kg Administration:Oral administration; daily; for 16 weeks Result:Significantly reduced the numbers of ACF in colon cancer rats. Also markedly decreased COX-2 protein expression.
-
Synonyms——
-
PathwayChromatin/Epigenetic
-
TargetCOX
-
RecptorCOX-1|ROS
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number36062-05-2
-
Formula Weight374.43
-
Molecular FormulaC21H26O6
-
Purity>98% (HPLC)
-
SolubilityDMSO:45 mg/mL (120.19 mM; Need ultrasonic)
-
SMILESO=C(CC(O)CCC1=CC=C(O)C(OC)=C1)CCC2=CC=C(O)C(OC)=C2
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Srimuangwong K, et al. Hexahydrocurcumin enhances inhibitory effect of 5-fluorouracil on HT-29 human colon cancer cells. World J Gastroenterol. 2012 May 21;18(19):2383-9.
molnova catalog
related products
-
SC57666
SC57666 is a highly selective COX2 inhibitor (IC50 at 26 nM) that shows no activity against COX1.
-
Bufexamac
Bufexamac is a COX inhibitor for IFN-α release.
-
(+)-Catechin pentaac...
(+)-Catechin pentaacetate (Catechin pentaacetate) is an esterified derivative of catechin with the potential to improve intestinal morphology and function and positively modulate the microbiome, and reduce iron and zinc transport proteins in the duodenum.
